Monoclonal Antibody Therapy at OhioHealth

Monoclonal Antibody Therapy at OhioHealth

Monoclonal Antibody Therapy at OhioHealth

Gain a deeper understanding of these therapies for COVID-19 and review the symptoms and high-risk factors necessary to be a candidate for treatment, and the process for receiving the medication.

 

Talk to your doctor

If you have tested positive for COVID-19, have been experiencing symptoms for less than seven days, and have a high-risk factor (as listed below), you may be eligible to receive this treatment. Contact your primary care provider. 

 

Fast facts about monoclonal antibodies

Joe Gastaldo, MD, OhioHealth’s system medical director of infectious disease, explains how monoclonal antibodies work, which patients the therapy is a good fit for, and the potential side effects and complications.

 

Who can receive monoclonal antibody therapy?

OhioHealth has supplies of two monoclonal antibody therapies that received emergency use authorization from the U.S. Food and Drug Administration (FDA). In published studies, monoclonal antibodies decrease a patient’s viral load, which may reduce the possibility of disease progression and hospitalization.

The two monoclonal antibody therapies are called:

  • Bamlanivimab and Etesevimab
  • Casirivimab and Imdevimab

Both are medications still being studied, but the FDA has authorized the emergency use of both medications for the treatment of COVID-19.

  • Monoclonal antibody treatment is restricted to outpatient ambulatory therapy only. Patients must have confirmed COVID-19, one or more high-risk factors, and symptoms for seven days or less. Patients receive treatment at dedicated locations or at home.
  • Patients who have one or more high-risk factors can be referred for monoclonal antibody treatment. Patients who have two or more high-risk factors will be prioritized for treatment. 

COVID-19 symptoms, high-risk factors and exclusion criteria

Qualifying COVID-19 symptoms
  • Chills
  • Cough
  • Diarrhea
  • Documented temperature above 100 F (37.8 C)
  • Fatigue
  • Headache
  • Loss of taste or smell
  • Nasal discharge
  • Nasal obstruction or congestion
  • Nausea or vomiting
  • Shortness of breath
  • Sore throat
  • Subjective fever or feverish feeling
High-risk factors
  • Age 65 or older
  • Body mass index (BMI) above 25 or BMI above the 85th percentile for pediatrics
  • Chronic kidney disease
  • Diabetes
  • Pregnancy
  • Cardiovascular disease, hypertension, or chronic lung disease
  • Sickle cell disease
  • Neurodevelopmental disorders, such as cerebral palsy
  • Medically related technological dependence, such as a tracheostomy or gastrostomy
  • Immunosuppressive disease or treatment:
    • Chemotherapy for cancer
    • Within one year of hematopoietic stem cell or solid organ transplant
    • Untreated HIV infection with CD4 T lymphocyte count below 200, or a CD4 percentage below 14%
    • Combined primary immunodeficiency disorder
    • Receiving prednisone above 20 milligrams a day for more than 14 days
Exclusion criteria

Monoclonal antibody treatment is not authorized for use in patients who are:

  • Hospitalized due to COVID-19
  • Receiving oxygen therapy due to COVID-19
  • Receiving chronic oxygen therapy due to an underlying non-COVID-19 related comorbidity, and require an increase in baseline oxygen flow rate due to COVID-19.

The monoclonal antibody treatment process

  • Submitted physician referrals are reviewed by a special multidisciplinary committee at OhioHealth.
  • If your patient is approved for therapy, we will contact them to schedule an appointment at one of our dedicated treatment locations, or in their home. We try to contact patients within 24 hours, but it may take longer over the weekend.
  • Monoclonal antibody treatment is an infusion therapy, delivered intravenously in one dose, in 30-60 minutes, depending on the medication. The overall infusion process takes three to four hours, which includes setup, infusion, and observation after treatment.
  • Visitors are not permitted. Patients are welcome to bring a book or reading material.

Cost for the treatment and infusion

OhioHealth is providing COVID-19 infusion treatments for no cost to our community. We will not bill you for any balance, deductible, copay or coinsurance. However, be aware that if you have insurance, OhioHealth will bill your insurance provider for the cost to administer the infusion. If you do not have insurance, the government will cover the cost to administer the infusion via the CARES Act. Call the OhioHealth Price Line with questions at (614) 566-8707 or (toll free) (844) 393-1035.

COVID-19 Vaccine

The Centers for Disease Control (CDC) recommends that vaccination for COVID-19 should be deferred for at least 90 days after a patient is treated with monoclonal antibodies to avoid interference of the treatment with vaccine-induced immune responses.

If a patient has received the COVID-19 vaccine, that should not impact the decision to recommend treatment with monoclonal antibodies. If a patient has only had one vaccine dose and chooses to get monoclonal antibodies, the second vaccine dose should be administered 90 days post-infusion. The patient does not have to restart the vaccine series.

Monoclonal antibody infusion locations

OhioHealth Mansfield Hospital
335 Glessner Avenue
Mansfield, Ohio 44903
(567) 309.2036

OhioHealth Hardin Memorial Hospital
921 East Franklin Street
Kenton, Ohio 43326
(567) 295.6900

OhioHealth Marion Infusion Services
1000 McKinley Park Drive
Marion, Ohio 43302
(740) 383.8506

OhioHealth O'Bleness Hospital
30 Herrold Avenue
Athens, Ohio 45701

OhioHealth Grove City Health Center
2030 Stringtown Road, Suite 120
Grove City, Ohio 43123
(614) 544.0143

OhioHealth At Home – Advanced Home Services
(614) 566.0300